Anti-Mullerian Hormone (AMH) Blastocyst Cryopreservation

Study shows that AMH predicts surplus good quality blastocyst cryopreservation

Couples who proceed with IVF hope to achieve a live birth with their fresh IVF cycle and most also hope to have surplus embryos for cryopreservation in order to have the opportunity for future attempts at pregnancy. In prior studies in the medical literature, AMH has been shown to predict ovarian response to gonadotropins, the injectable medications that are used to grow follicles for IVF. Some studies have shown that Anti-Mullerian Hormone (AMH) predicts the probability for live birth whereas others have not been able to show an association between AMH levels and live birth rates.

“We wanted to see if AMH predicts the probability of supernumerary blastocyst stage embryos for cryopreservation,” states Dr. Shahryar Kavoussi. “Our publication in the Fertility & Sterility is of value to clinicians in terms of being able to counsel patients, based on AMH level, about the coveted secondary outcome of a fresh cycle, namely the probability of supernumerary blastocyst cryopreservation in order to provide future attempts at pregnancy with frozen-thawed embryo transfer (FET) as an extension of the fresh IVF cycle”. This study showed that low AMH levels predict a lower likelihood of blastocysts for cryopreservation as compared with higher AMH levels.

Click here or visit the link below to read the full text Open Access article published in Fertility & Sterility: